Who understands drug pricing?; Walgreens eyes more tie-ups with pharma; Biogen, SOBI roll out Elocta in Europe;

@FiercePharma: Healthcare agency, top drugmakers spotlight growing role in public health at UN meeting. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: Waiting for flight/playing "guess where these guys work based on overheard description of latest clinical trial failure." | Follow @CarlyHFierce

> The complex--and often secret--nature of drug pricing in the U.S. has complicated public debate about the issue. Report

> Walgreens ($WBA) says it's looking at follow-up specialty pharmacy deals with drugmakers now that it has sealed a pact with troubled Valeant Pharmaceuticals ($VRX) on a slate of meds. Report

> Swedish Orphan Biovitrum said Elocta, a long-acting hemophilia A treatment it developed with Biogen ($BIIB), has been launched in Europe. Release

> SkyePharma said it expects to beat its 2015 forecast thanks to a sales-related milestone payment from its partner on the respiratory med flutiform, Mundipharma. Report

> Valneva said its Japanese encephalitis vaccine won approval in Taiwan through its partner there, Adimmune. Report

Medical Device News

@FierceMedDev: ICYMI: Israeli startup raises $10M to back transcatheter aortic valve stenosis treatment. Article | Follow @FierceMedDev

@EmilyWFierce: Who's on board with Twitter's 10,000 character limit? Pharma brand managers. FiercePharmaMarketing story | Follow @EmilyWFierce

@VarunSaxena2: ICYMI: Startup raises $14M to commercialize its filter to prevent blood clots during hospitalization. Article | Follow @VarunSaxena2

> Illumina focuses on 'holy grail market opportunity' with liquid biopsy spinoff. Article

> Thermo Fisher to buy Affymetrix for $1.3B to beef up in genetic analysis. Report

> JPM: Med tech 'innovation studio' debuts thanks to $15M investment from American Medical Association. Story

Biotech News

@FierceBiotech: The Bradner factor: Roche bags a BET inhibitor in $535M Tensha buyout. Article | Follow @FierceBiotech

@JohnCFierce: Shire finally gets it done, bagging Baxalta in $32B buyout. News | Follow @JohnCFierce

> Accelerator's second NYC biotech startup sets out with $17M and some Gates-backed science. Story

> Sanofi commits €400M to another cancer R&D pact, this time with Innate Pharma. More

> Landmark $1.9B-plus deal for Seres includes PhIII support. Article

Animal Health News

> USDA shifts attention to diagnostics to curb deadly pig virus. More

> China Animal Healthcare creates embarrassment for stakeholder Lilly. Report

> Startup AGL launches dog-collar sensor for remote tracking of chronic illnesses. Story

> Researchers ID link between fish-flavored cat food and thyroid disease. Item

> Zoetis offloads manufacturing sites as CFO embraces activist investors. Article

Biotech IT News

> Roche leads $175M investment in oncology software player Flatiron. News

> MC10 pitches data-gathering wearable patch at research community. Report

> Pfizer taps Adaptive to add NGS, bioinformatics skills to immuno-oncology drive. Story

> Michael J. Fox Foundation signs up for wearable-enabled Phase III trial project. Item

> Vertex inks deal to add Genomics' database, algorithms to drug discovery toolkit. Article

Pharma Marketing News

> Who's on board with Twitter's 10,000 character limit? Pharma brand managers. Story

> Will GSK's no-speaker-fee system work? Execs say yes; critics, not so much. More

> Healthcare agency, top drugmakers spotlight growing role in public health at UN meeting. Article

> Shire to take on hemophilia marketing with long-sought Baxalta buy. Item

And Finally... A large new study, published in the BMJ, found no risk of birth defects from oral contraceptives. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.